# Tislelizumab Combined With Chemotherapy Versus Chemotherapy Alone in Recurrent or Metastatic Nasopharyngeal Cancer (NPC)

> **NCT03924986** · PHASE3 · COMPLETED · sponsor: **BeiGene** · enrollment: 263 (actual)

## Conditions studied

- Recurrent or Metastatic Nasopharyngeal Cancer

## Interventions

- **DRUG:** Tislelizumab
- **DRUG:** Placebo
- **DRUG:** Gemcitabine
- **DRUG:** Cisplatin

## Key facts

- **NCT ID:** NCT03924986
- **Lead sponsor:** BeiGene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-03-27
- **Primary completion:** 2021-03-26
- **Final completion:** 2023-12-08
- **Target enrollment:** 263 (ACTUAL)
- **Last updated:** 2025-01-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03924986

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03924986, "Tislelizumab Combined With Chemotherapy Versus Chemotherapy Alone in Recurrent or Metastatic Nasopharyngeal Cancer (NPC)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03924986. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*